Interpretation systems for genotypic drug resistance of HIV-1

References

• Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999; 353: 2195–9.
   PubMed Web of Science ®Google Scholar
• Baxter JD, Mayers BL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, et al. A randomized study of antiretroviral management based on plasma genotypic resistance testing in patients failing therapy. AIDS 2000; 14: F83–93.
   PubMed Web of Science ®Google Scholar
• Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, Gonzalez J, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 2002; 16: 209–18.
   PubMed Web of Science ®Google Scholar
• Cingolani A, Antinori A, Rizzo MG, Murri R, Ammassari A, Baldini F, et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS 2002; 16: 369–79.
   PubMed Web of Science ®Google Scholar
• Calvin JC, Hunt S, Sension M, Farthing C, Conant M, Jacobson S, et al., VIRA3001 Study Team. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS. 2002; 16: 579–88.
   Google Scholar
• Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin G, et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS 2002; 16: 727–36.
   Google Scholar
• Hirsch MS, Brun-Vezinet F, D’Aquila RT, Hammer SM, Johnson VA, Kuritzkes DR, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA 2000; 283: 2417–26.
   PubMed Web of Science ®Google Scholar
• The EuroGuidelines Group for HIV Resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. AIDS. 2001; 15: 309–20.
   PubMed Web of Science ®Google Scholar
• International AIDS Society USA Resistance Testing Guidelines Panel. Topics HIV Med 2001; 9: 31–3.
   Google Scholar
• Schinazi RF, Larder B, Mellors JW. Int Antiviral News 2000; 8: 65–91.
   Google Scholar
• Shafer RW, Jung DR, Betts BJ, Xi Y, Gonzales MJ. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 2000; 28: 346–8.
   Google Scholar
• DeGruttola V, Dix L, D’Aquila R, Holder D, Phillips A, Ait-Khaled M, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 2000; 5: 41–8.
   Google Scholar
• Larder BA, Kemp SD, Hertogs K. Quantitative prediction of HIV-1 phenotypic drug resistance from genotypes: the virtual phenotype (VirtualPhenotype). Antivir Ther 2000; 5\(Suppl 3): 49–50.
   Google Scholar
• Menéndez-Arias L. Summary of mutations involved in resistance to antiretroviral drugs. In: Clotet B, Menéndez-Arias L, Ruiz L, Tural C, Brun Vezinet F, Loveday C, et al, eds. Guide to management of HIV drug resistance and pharmacokinetics of antiretroviral therapy, 2nd ed. Barcelona: TAISA; 2002. p. 196–202.
   Google Scholar
• Van Laethem K, De Luca A, Antinori A, Cingolani A, Perno CF, Vandamme AM. A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-infected patients. Antivir Ther 2002; 7: 123–9.
   PubMed Web of Science ®Google Scholar
• Boulme R, Halfon P, Diaz R, Dugas O, Schmit JC. Comparative evaluation between five automated resistance interpretation algorithms. 5th International Workshop on HIV Drug Resistance and Treatment Strategies, Scottsdale, USA, 4–8 June 2001. Abstract 156. Antivir Ther 2001; 6\(Suppl 1): 121.
   Google Scholar
• Retrogram 1.6. www.retrogram.com
   Google Scholar
• Visible Genetics. www.visgen.com and www.trugene.com/Physicians/GuideLineRules_5.0.pdf Update at: http://www.trugene. com/Physicians/GuideLines_6.0_Rules.pdf
   Google Scholar
• Reid C, Bassett R, Day S, Larder B, DeGruttola V, Winslow D. A dynamic rules-based interpretation system derived by an expert panel is predictive of virological failure. XI International HIV drug resistance workshop. Basic principles and clinical implications. Abstract 112. Antivir Ther 2002; 7\(Suppl 1): S91.
   Google Scholar
• Stanford website database. http://hivdb.stanford.edu
   Google Scholar
• Hammer S, Peeters M, Harrihan R, Larder B. Virtual phenotype is predictive of treatment failure in treatment-experienced patients. 5th International Workshop on HIV Drug Resistance and Treatment Strategies, Scottsdale, USA, 4–8 June 2001. Antivir Ther 2001; 6\(Suppl 1): 107.
   Google Scholar
• Tibotec-Virco. www.vircolab.com
   Google Scholar
• French government guidelines. http://www.sante.gouv.fr/htm/actu/rap_delf/4_genotype.htm Update at: http://perso.club-internet.fr/pugliese/index.htm
   Google Scholar
• International Medical Press. http://www.mediscover.net/antiviralintro.cfm
   Google Scholar
• Intelligent Therapeutic Solutions. http://www.therapyedge.com
   Google Scholar
• Advanced Biological Laboratories. http://www.ablnetworks.org.
   Google Scholar
• Los Alamos website resistance database. http://www.hiv.lanl.gov/ADRA/adra.html
   Google Scholar
• Beerenwinkel N, Schmidt B, Walter H, Kaiser R, Lengauer T, Hoffmann D, et al. Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting phenotype from genotype. Proc Natl Acad Sci USA 2002; 99: 8271–6.
   PubMed Web of Science ®Google Scholar
• AREVIR ‘geno2pheno’. http://cartan.gmd.de/geno2pheno.html Update at: http://www.genafor.org
   Google Scholar
• International AIDS Society-USA. http://hivinsite.ucsf.edu/medical/resistance/2098.474c.html Update at: http://www.iasusa.org/resistance_mutations/resistance.pdf
   Google Scholar
• Specialty laboratories. www.specialtylabs.com
   Google Scholar
• HIVresistanceWeb, Vertibrae. http://www.hivresistanceweb.com/protected/mutationtables/
   Google Scholar
• Piketty C, Race E, Castiel P, Belec L, Peytavin C, Si-Mohamed A, et al. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy. AIDS 1999; 12: F71–7.
   Google Scholar
• Castagna A, Danese A, Hasson H, Boeri E, Lazzarin A, Peeters M, et al. The normalized inhibitory quotient (NIQ of lopinavir is predictive of viral load response over 48 weeks in a cohort of highly experienced HIV-infected individuals. 9th Conference on Retroviruses and Opportunistic Infections, Seattle, USA, 24–28 February 2002. Abstract 128.
   Google Scholar
• Haubrich R, Keiser P, Kemper C, Witt M, Leedom J, Forthal D, et al. CCTG 575: a randomized, prospective study of phenotype testing versus standard of care for patients failing antiretroviral therapy. Antivir Ther 2001; 6(Suppl 1): 63.
   PubMed Web of Science ®Google Scholar
• Ravela J, Betts BJ, Brun-Vezinet F, Vandamme AM, Descamps D, van Laethem K, et al. HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms. J Acquir Immune Defic Syndr 2003; 33: 8–14.
   Google Scholar
• De Luca A, Cingolani A, Di Giambenedetto S, Trotta MP, Baldini F, Rizzo MG, et al. Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance. J Infect Dis 2003; 187: 1934–43.
   PubMed Web of Science ®Google Scholar
• Lanier R, Scott J, Ait-Khaled M, Stone C, Melby T, Sturge G, et al. Predicting abacavir antiviral activity using HIV-1 genotype: a comparison of 12 algorithms. 5th International Workshop on HIV Drug Resistance and Treatment Strategies, Scottsdale, USA, 4–8 June 2001. Antivir Ther 2001; 6\(Suppl 1): 103.
   Google Scholar